Company intelligence / Profile preview
Klinge Biopharma
Holzkirchen, Bavaria, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Klinge Biopharma, through licensing partnerships, commercializes biosimilars in ophthalmologic, immunologic, and other therapy areas. The FDA and EMA approved FYB203 (aflibercept biosimilar/AHZANTIVE®) in 2024-2025 for major retinal indications, and Klinge is the global commercialization rightsholder for this product, with Teva and others handling region-specific launches. The company also sells established brands and generics in Germany.
- Therapeutic areas
- Ophthalmology
- Modalities
- BiologicBiosimilarSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Teva Pharmaceutical IndustriesFormyconCoherus BioSciences (USA - FYB203)Valorum Biologics (USA - FYB203)
Beyond the preview
Go deeper on Klinge Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Klinge Biopharma.